Harnessing the Power of ROR1

VelosBio is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer.

About Us


ROR1 cell-surface protein is expressed on many hematologic and solid tumors. VelosBio’s proprietary ROR1-targeting technology allows the selective delivery of ROR1-directed therapies to tumors while sparing normal tissues.

Our Science
Homepage Bi Ab alt


Led by industry veterans with a track record of delivering new oncology drugs to patients, VelosBio Inc. is committed to improving patient outcomes by creating innovative targeted therapies for patients with hematologic and solid tumor malignancies.